Current Report Filing (8-k)
April 28 2021 - 4:09PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange
Act of 1934
Date of Report (Date of earliest event reported): April
28, 2021
NEMAURA MEDICAL INC.
(Exact name of registrant as specified in its charter)
Nevada
|
|
001-38355
|
|
46-5027260
|
(State or other jurisdiction of
incorporation or organization)
|
|
(Commission
File Number)
|
|
(I.R.S. Employer
Identification Number)
|
57 West 57th Street
Manhattan, NY
|
|
10019
|
(Address of principal executive offices)
|
|
(Zip Code)
|
|
|
|
Registrant’s telephone number, including area code:
|
|
(646) 416-8000
|
|
|
|
N/A
|
(Former name or former address, if changed since last report)
|
Check the appropriate box below if the Form 8-K filing
is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
[_]
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
[_]
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
[_]
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
[_]
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
|
|
Trading Symbol(s)
|
|
Name of each exchange on which registered
|
Common Stock
|
|
NMRD
|
|
The Nasdaq Stock Market LLC
|
Indicate by check mark whether the registrant is an
emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities
Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company [_]
If an emerging growth company, indicate by check mark
if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards
pursuant to Section 13(a) of the Exchange Act. [_]
Item 2.02
|
Results of Operations and Financial Condition.
|
On April 28, 2021, management of Nemaura Medical
Inc. (the “Company”) will hold a conference call today (April 28, 2021) at 4:30 p.m. Eastern time to provide a
shareholder update. Among other things, management will announce that (i) the Company expects to report revenues in relation to
sales of sugarBEAT in the UK / European market during the quarter ending September 30, 2021, (ii) as of the year ended March 31,
2021, cash held on the balance sheet stood at $31.8 million, and (iii) the historical cash burn rate has been less than $2 million
per quarter.
The information under this Item 2.02 is being furnished
and shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the
“Exchange Act”), or otherwise subject to the liabilities of such section, nor shall such information be deemed incorporated
by reference in any filing under the Securities Act of 1933, as amended (the “Securities Act”), or the Exchange Act, except
as shall be expressly set forth by specific reference in such filing.
Item 7.01.
|
Regulation FD Disclosure.
|
The information set forth under Item 2.02 of this
Current Report on Form 8-K is incorporated herein by reference.
The information under this Item 7.01 is being furnished
and shall not be deemed to be “filed” for the purposes of Section 18 of the Exchange Act, or otherwise subject to the liabilities
of such section, nor shall such information be deemed incorporated by reference in any filing under the Securities Act or the Exchange
Act, except as shall be expressly set forth by specific reference in such filing. The information set forth under this Item 7.01 shall
not be deemed an admission as to the materiality of any information in this Current Report on Form 8-K.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Dated: April 28, 2021
|
NEMAURA MEDICAL INC.
|
|
|
|
By:
|
/s/ Dewan F. H. Chowdhury
|
|
Name:
Title:
|
Dewan F. H. Chowdhury
Chief Executive Officer
|
Nemaura Medical (NASDAQ:NMRD)
Historical Stock Chart
From Jun 2024 to Jul 2024
Nemaura Medical (NASDAQ:NMRD)
Historical Stock Chart
From Jul 2023 to Jul 2024